Understand the impact of the Ukraine conflict from a cross-sector perspective with the Global Data Executive Briefing: Ukraine Conflict

Pfizer has announced that it has no intention to make additional investments in Russia amid the Ukraine crisis, CEO Albert Bourla said in an exclusive interview to CBS News.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company will not stop its business with Russia, he told during Face the Nation, an American Television programme.

Pfizer will not cut ties with Russia completely, Bourla said, adding that the company manufactures some therapies intended for the region in the country itself and does not export from Russia. 

Owing to humanitarian reasons, the trade restrictions usually exclude lifesaving therapies, he added. 

Bourla said: “How can you say I’m not going to send the cancer medicines to Russians because of what they did.” 

He also stated that Pfizer has limited exposure in Russia and any financial consequences from the Russia-Ukraine war will be ‘very minimal’ to the company’s outcome. 

Russia accounts for under 0.5% of Pfizer’s total revenue and the company does not anticipate any supply chain disruptions or price pressure due to the Russia-Ukraine crisis.

Bourla added: “We are very independent in terms of our supplying our ingredients from those parts of the world. 

“We do not expect to see in the world any disruptions, right now at least, because of this war.”

In February 2022, Pfizer recorded revenues of $81.3bn for the full year 2021, signifying a 92% operational growth versus $41.7bn for the full year 2020.

The revenue for the full year increased by 6% operationally to $44.4bn on excluding the contributions of Comirnaty and Paxlovid.